Safety and Efficacy of Inotersen in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (NEURO-TTR) (N2.001)

Morie A. Gertz(Medical University of South Carolina), Merrill D. Benson(Indiana University School of Medicine), Stephen B. Heitner(Brigham and Women's Hospital), Giuseppe Vita(University of Messina), Peter D. Gorevic(Université Paris-Sud), John L. Berk(Boston University), Jesse Kwoh(Ionis Pharmaceuticals (United States)), Márcia Waddington‐Cruz(Université Paris-Sud), Annabel K. Wang(Université Paris-Sud), Brenda F. Baker(Ionis Pharmaceuticals (United States)), Josep M. Campistol(Universitat de Barcelona), Violaine Planté‐Bordeneuve(Université Paris-Est Créteil), Brett P. Monia(Ionis Pharmaceuticals (United States)), Fábio Barroso(Université Paris-Sud), Acary Souza Bullé Oliveira(Universidade Federal de São Paulo), Carol Whelan(The Royal Free Hospital), Thomas H. Brannagan(Columbia University), Isabel Conceição(Université Paris-Sud), Brian Drachman(Penn Presbyterian Medical Center), Steven G. Hughes(Ionis Pharmaceuticals (United States)), Michael Polydefkis(Université Paris-Sud), Josep Gámez(Université Paris-Sud), Giampaolo Merlini(University of Pavia), Morton Scheinberg(Université Paris-Sud), Edward Gane(University of Auckland), David Adams(Mount Sinai Health System), Teresa Coelho(Universidade do Porto), Elizabeth J. Ackermann(Université Paris-Sud), P. James B. Dyck(Mayo Clinic), Harmut Schmidt(University Hospital Münster), Bradley McEvoy(Université Paris-Sud)

Neurology

April 10, 2018

Cited by 1

Related Papers

|New England Journal of Medicine|2019|3.6k

|New England Journal of Medicine|2018|2.9k

|New England Journal of Medicine|2018|2.8k

|Leukemia|2006|2.6k

|Cell Metabolism|2006|2.1k